IgG from atopic dermatitis patients induces non-atopic infant thymic invariant natural killer T (iNKT) cells to produce IL-4, IL-17, and IL-10
Carregando...
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
SGNOTTO, Fabio da Ressureicao
Citação
INTERNATIONAL JOURNAL OF DERMATOLOGY, v.59, n.3, p.359-364, 2020
Resumo
Background Atopic dermatitis (AD) pathogenesis still needs to be elucidated, but invariant natural killer T (iNKT) cell involvement was already described by several groups. Our group has demonstrated that IgG antibodies purified from AD patients can modulate cytokine production by thymic T cells. Here we aimed to investigate if IgG from AD patients can modulate infant non-atopic thymic iNKT cells cytokine production in order to collaborate with the elucidation of AD development in infancy. Methods Thymic tissues were obtained from children from non-atopic mothers, and IgG was purified from AD patients diagnosed as moderate or severe and, as controls, from subjects clinically classified as non-atopic individuals. PBMCs from non-atopic individuals were also used in this study. Results Our results demonstrated that IgG from AD patients could induce non-atopic children thymic iNKT cells to produce higher levels of intracellular IL-4, IL-10, and IL-17 when compared to all control conditions. No effect was observed in non-atopic adults peripheral iNKT. We also observed that IgG from AD patients induces an increase in the expression of CD4 and Ror gamma t transcription factor in non-atopic children thymic iNKT cells compared to the condition of all controls. Conclusions These observations suggest that IgG from AD patients can induce a cytokine profile by thymic iNKT cells from non-atopic infants compatible with the observations in AD development, which can collaborate with the elucidation of AD pathogenesis.
Palavras-chave
Referências
- Batista DIS, 2015, J EUR ACAD DERMATOL, V29, P1091, DOI 10.1111/jdv.12753
- Bento-de-Souza Luciana, 2016, Results Immunol, V6, P15, DOI 10.1016/j.rinim.2016.04.001
- Sgnotto FD, 2017, HUM VACC IMMUNOTHER, V13, P1563, DOI 10.1080/21645515.2017.1299299
- Davodeau F, 1997, J IMMUNOL, V158, P5603
- Lira AAD, 2018, ALLERGOL IMMUNOPATH, V46, P454, DOI 10.1016/j.aller.2018.04.001
- de Oliveira MG, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-017-0195-8
- de-Oliveira MG, 2019, CLIN EXP ALLERGY, V49, P1000, DOI 10.1111/cea.13393
- Futata EA, 2006, IMMUNOBIOLOGY, V211, P157, DOI 10.1016/j.imbio.2005.08.006
- Gyimesi E, 2011, J CLIN IMMUNOL, V31, P864, DOI 10.1007/s10875-011-9551-5
- Heinzerling Lucie, 2013, Clin Transl Allergy, V3, P3, DOI 10.1186/2045-7022-3-3
- Lemieux W, 2005, MOL IMMUNOL, V42, P839, DOI 10.1016/j.molimm.2004.07.046
- Orfali RL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25125-0
- Rachitskaya AV, 2008, J IMMUNOL, V180, P5167, DOI 10.4049/jimmunol.180.8.5167
- Santos LS, 2019, ARCH IMMUNOL THER EX, V67, P263, DOI 10.1007/s00005-019-00545-6
- Sgnotto FDR, 2018, INT J DERMATOL, V57, P434, DOI 10.1111/ijd.13907
- Takahashi T, 2003, HUM IMMUNOL, V64, P586, DOI 10.1016/S0198-8859(03)00066-1
- Victor JR, 2017, HUM VACC IMMUNOTHER, V13, P507, DOI 10.1080/21645515.2016.1244592
- Victor JR, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/780386
- Wu WH, 2010, J ALLERGY CLIN IMMUN, V126, P290, DOI 10.1016/j.jaci.2010.05.024